Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free ABEO Stock Alerts

Abeona Therapeutics (ABEO) Financials

Abeona Therapeutics logo
$6.05 -0.33 (-5.17%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$6.14 +0.09 (+1.54%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Abeona Therapeutics

Annual Income Statements for Abeona Therapeutics

This table shows Abeona Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -15 -22 -27 -57 -76 -84 -85 -43 -54 -64 71
Consolidated Net Income / (Loss)		 -15 -22 -27 -57 -76 -84 -85 -40 -54 -64 71
Net Income / (Loss) Continuing Operations		 -15 -22 -27 -57 -76 -84 -85 -40 -54 -64 71
Total Pre-Tax Income 		-15 -22 -27 -57 -76 -84 -92 -40 -57 -64 71
Total Operating Income		 -19 -24 -28 -58 -77 -81 -90 -51 -47 -64 -89
Total Gross Profit		 1.04 0.29 0.84 0.20 0.00 10 3.00 1.41 3.50 0.00 4.29
Total Revenue		 1.04 0.29 0.84 0.20 0.00 10 3.00 1.41 3.50 0.00 5.82
Operating Revenue		 1.04 0.29 0.84 0.20 0.00 10 3.00 1.41 3.50 0.00 5.82
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.53
Operating Cost of Revenue		 - - - - - - - - - 0.00 1.53
Total Operating Expenses		 20 24 29 58 77 91 93 52 51 64 94
Selling, General & Admin Expense		 14 13 11 20 21 57 22 17 19 30 65
Research & Development Expense		 4.72 11 17 39 49 30 39 29 31 34 27
Other Operating Expenses / (Income)		 - -0.60 0.00 -2.80 - - 0.00 2.96 0.54 0.00 1.89
Total Other Income / (Expense), net		 4.02 2.01 0.52 1.50 0.81 -2.81 -1.86 11 -10.00 0.48 161
Interest Expense		 0.01 0.01 0.01 0.01 0.40 4.12 3.66 0.74 0.42 4.21 3.74
Interest & Investment Income		 4.03 2.01 0.53 1.51 1.21 1.30 0.04 0.43 2.12 4.25 5.56
Other Income / (Expense), net		 - - - - - 0.00 1.76 11 -12 0.44 159
Income Tax Expense		 - - - - - - - - - 0.00 0.10
Basic Earnings per Share		 ($0.53) ($0.64) ($0.66) ($1.19) ($1.51) ($0.91) ($21.57) ($5.53) ($2.53) ($1.55) $1.34
Weighted Average Basic Shares Outstanding		 27.60M 34.18M 41.64M 47.53M 50.35M 92.66M 3.94M 7.86M 21.38M 41.05M 52.95M
Diluted Earnings per Share		 ($0.53) ($0.64) ($0.66) ($1.19) ($1.51) ($0.91) - ($5.53) ($2.53) ($1.55) $1.01
Weighted Average Diluted Shares Outstanding		 27.60M 34.18M 41.64M 47.53M 50.35M 92.66M 98.44M 7.86M 21.38M 41.05M 66.14M
Weighted Average Basic & Diluted Shares Outstanding		 27.60M 34.18M 41.64M 47.53M 50.35M 92.66M 98.44M 17.71M 27.36M 48.53M 57.05M

Quarterly Income Statements for Abeona Therapeutics

This table shows Abeona Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -12 -17 -32 7.41 -30 -9.39 -12 109 -5.16 -20 -17
Consolidated Net Income / (Loss)		 -12 -17 -32 7.41 -30 -9.29 -12 109 -5.16 -20 -17
Net Income / (Loss) Continuing Operations		 -12 -17 -32 7.41 -30 -9.29 -12 109 -5.16 -20 -17
Total Pre-Tax Income 		-12 -17 -32 7.41 -30 -9.96 -12 124 -20 -21 -17
Total Operating Income		 -11 -13 -14 -18 -15 -17 -20 -23 -24 -23 -23
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.40 -0.49 4.38 6.02
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.40 0.00 5.42 8.72
Operating Revenue		 0.00 - 0.00 0.00 0.00 - - 0.40 0.00 5.42 8.72
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.49 1.04 2.70
Operating Cost of Revenue		 - - - - 0.00 - 0.00 - 0.49 - 2.70
Total Operating Expenses		 11 13 14 18 15 17 20 23 24 27 29
Selling, General & Admin Expense		 4.16 5.83 7.12 8.65 6.40 7.68 9.79 17 19 19 20
Research & Development Expense		 7.15 7.38 7.21 9.22 8.94 8.99 9.94 5.94 4.22 6.71 9.56
Total Other Income / (Expense), net		 -0.61 -3.60 -17 25 -15 6.72 7.70 147 3.66 2.38 5.96
Interest Expense		 0.11 0.11 0.95 1.07 1.10 1.08 1.00 0.96 0.90 0.88 0.83
Interest & Investment Income		 0.59 0.74 0.84 1.19 1.19 1.02 1.31 153 1.67 -151 1.35
Other Income / (Expense), net		 -1.10 -4.23 -17 25 -15 6.78 7.39 -5.30 2.89 154 5.44
Income Tax Expense		 - - - 0.00 0.00 - 0.00 16 -15 - 0.00
Basic Earnings per Share		 ($0.48) ($0.77) ($1.16) $0.19 ($0.63) $0.05 ($0.24) $2.07 ($0.10) ($0.39) ($0.30)
Weighted Average Basic Shares Outstanding		 24.80M 21.38M 27.32M 40.01M 48.08M 41.05M 49.78M 52.52M 54.24M 52.95M 56.62M
Diluted Earnings per Share		 ($0.48) ($0.77) ($1.16) ($0.26) ($0.63) $0.50 ($0.24) $1.71 ($0.10) ($0.36) ($0.30)
Weighted Average Diluted Shares Outstanding		 24.80M 21.38M 27.32M 51.23M 48.08M 41.05M 49.78M 66.64M 54.24M 66.14M 56.62M
Weighted Average Basic & Diluted Shares Outstanding		 24.77M 27.36M 41.19M 43.31M 43.47M 48.53M 51.16M 51.28M 54.19M 57.05M 57.00M

Annual Cash Flow Statements for Abeona Therapeutics

This table details how cash moves in and out of Abeona Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 29 29 69 -119 111 -117 25 -24 0.26 8.88 55
Net Cash From Operating Activities		 -10 -13 -23 -39 -63 -35 -66 -43 -37 -56 -76
Net Cash From Continuing Operating Activities		 -10 -13 -23 -39 -63 -35 -66 -43 -37 -56 -76
Net Income / (Loss) Continuing Operations		 -15 -22 -27 -57 -76 -84 -85 -40 -54 -64 71
Consolidated Net Income / (Loss)		 -15 -22 -27 -57 -76 -84 -85 -40 -54 -64 71
Depreciation Expense		 0.55 0.83 0.74 2.36 7.82 4.59 3.25 3.09 2.29 2.00 2.55
Amortization Expense		 - - - - - 1.02 1.34 1.10 0.82 1.18 1.90
Non-Cash Adjustments To Reconcile Net Income		 5.72 8.26 5.79 8.24 6.60 45 17 -7.09 15 2.60 -147
Changes in Operating Assets and Liabilities, net		 -2.17 -0.22 -1.87 6.96 -0.95 -1.53 -1.85 -0.89 -0.59 1.93 -4.81
Net Cash From Investing Activities		 3.39 -0.52 -0.86 -85 60 -84 66 -24 0.21 -39 105
Net Cash From Continuing Investing Activities		 3.39 -0.52 -0.86 -85 60 -84 66 -24 0.21 -39 105
Purchase of Property, Plant & Equipment		 -0.31 -0.52 -0.86 -9.24 -6.31 -1.34 -4.15 -0.13 -0.33 -2.45 -7.98
Purchase of Investments		 - 0.00 0.00 -136 0.00 -170 -20 -78 -52 -157 -207
Sale of Property, Plant & Equipment		 3.70 - - - - - 0.00 1.73 0.20 0.02 0.00
Sale and/or Maturity of Investments		 - 0.00 0.00 71 66 88 90 53 52 120 320
Net Cash From Financing Activities		 36 43 92 5.48 114 1.94 25 43 37 104 26
Net Cash From Continuing Financing Activities		 36 43 92 5.48 114 1.94 25 43 37 104 26
Repayment of Debt		 -0.40 - - - - - - 0.00 -0.15 -0.96 0.00
Issuance of Debt		 - - - - 0.00 1.76 - - 0.00 20 0.00
Issuance of Common Equity		 31 42 86 0.00 113 0.00 24 47 37 86 17
Other Financing Activities, net		 4.64 0.35 6.23 5.48 0.97 0.18 0.83 -0.01 -0.18 -0.53 8.74
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.00 0.00 - - 0.00 2.67 2.59
Cash Income Taxes Paid		 - - - - 0.00 0.00 - - 0.01 0.01 0.00

Quarterly Cash Flow Statements for Abeona Therapeutics

This table details how cash moves in and out of Abeona Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.51 9.76 3.09 17 -19 7.63 -7.42 148 -81 -4.79 -17
Net Cash From Operating Activities		 -5.75 -9.24 -15 -13 -12 -17 -18 -19 -21 -18 -20
Net Cash From Continuing Operating Activities		 -5.75 -9.24 -15 -13 -12 -17 -18 -19 -21 -18 -20
Net Income / (Loss) Continuing Operations		 -12 -17 -32 7.41 -30 -9.29 -12 109 -5.16 -20 -17
Consolidated Net Income / (Loss)		 -12 -17 -32 7.41 -30 -9.29 -12 109 -5.16 -20 -17
Depreciation Expense		 0.52 0.49 0.49 0.49 0.49 0.54 0.53 0.54 0.61 0.86 0.69
Amortization Expense		 0.44 0.00 0.17 0.19 0.36 0.46 0.74 0.06 0.19 0.92 0.19
Non-Cash Adjustments To Reconcile Net Income		 2.49 5.56 19 -23 17 -9.80 -4.58 -144 -0.85 1.79 4.66
Changes in Operating Assets and Liabilities, net		 2.65 1.31 -2.51 2.73 0.17 1.54 -3.06 15 -16 -1.07 -8.27
Net Cash From Investing Activities		 -19 12 -7.82 -44 -6.17 19 4.21 156 -65 9.55 4.96
Net Cash From Continuing Investing Activities		 -19 12 -7.82 -44 -6.17 19 4.21 156 -65 9.55 4.96
Purchase of Property, Plant & Equipment		 -0.04 -0.04 -0.73 -0.71 -0.40 -0.61 -1.40 -2.90 -2.52 -1.15 -0.94
Purchase of Investments		 -34 -3.42 -29 -61 -57 -10 -49 -20 -100 -38 -19
Sale and/or Maturity of Investments		 15 15 22 17 51 30 54 179 38 48 25
Net Cash From Financing Activities		 23 7.47 25 74 -0.30 5.31 6.77 10 5.16 3.61 -2.22
Net Cash From Continuing Financing Activities		 23 7.47 25 74 -0.30 5.31 6.77 10 5.16 3.61 -2.22
Repayment of Debt		 - -0.15 -0.96 - - - 0.00 - - - -2.22
Issuance of Common Equity		 23 7.79 6.42 74 - 5.51 6.80 11 - - 0.00
Other Financing Activities, net		 -0.00 -0.17 -0.01 -0.01 -0.30 -0.20 -0.03 -0.01 5.16 3.61 0.00
Cash Interest Paid		 - - 0.61 0.68 0.69 0.69 0.68 0.68 0.63 0.60 0.56

Annual Balance Sheets for Abeona Therapeutics

This table presents Abeona Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 80 111 179 174 223 151 80 64 64 109 220
Total Current Assets		 41 69 141 89 132 98 56 53 56 101 205
Cash & Equivalents		 40 69 138 19 129 13 33 14 14 23 78
Short-Term Investments		 - - 0.00 66 0.00 82 12 38 38 74 113
Accounts Receivable		 0.12 0.12 0.11 0.08 - - 3.00 0.19 2.44 1.65 6.72
Inventories, net		 - - - - - - - - - 0.00 5.49
Prepaid Expenses		 0.32 0.16 2.74 3.80 3.13 2.71 2.38 0.42 0.73 1.14 1.29
Plant, Property, & Equipment, net		 0.35 0.72 1.37 9.44 13 11 12 5.74 3.53 4.43 9.92
Total Noncurrent Assets		 39 41 37 76 78 42 11 5.37 4.73 3.65 4.74
Other Noncurrent Operating Assets		 0.06 0.07 0.36 0.60 9.19 8.17 9.57 5.37 4.73 3.65 4.74
Total Liabilities & Shareholders' Equity		 80 111 179 174 223 151 80 64 64 109 220
Total Liabilities		 12 12 8.67 40 45 49 37 37 49 65 60
Total Current Liabilities		 1.48 8.30 5.61 20 39 42 17 7.78 13 17 30
Short-Term Debt		 - - - - 0.00 0.33 - - 0.00 5.93 12
Accounts Payable		 0.88 3.69 1.88 16 31 36 8.92 1.81 1.86 3.44 7.89
Accrued Expenses		 - - 0.51 3.94 5.54 3.41 5.59 3.99 5.99 6.33 8.47
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 0.13
Other Current Liabilities		 0.00 4.00 0.00 0.00 1.70 1.71 2.11 1.98 5.58 0.89 0.86
Total Noncurrent Liabilities		 11 3.66 3.06 20 6.25 6.69 21 30 36 48 31
Long-Term Debt		 - - - - 0.00 1.43 - - 0.00 13 7.81
Noncurrent Deferred Revenue		 4.27 3.66 3.06 - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 6.59 - 0.00 0.00 6.25 5.26 17 30 36 35 23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 68 99 170 134 178 103 42 27 15 44 159
Total Preferred & Common Equity		 68 99 170 134 178 103 42 27 15 44 159
Preferred Stock		 - - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 68 99 170 134 178 103 42 27 15 44 159
Common Stock		 378 432 530 544 665 673 698 722 764 857 901
Retained Earnings		 -311 -332 -360 -410 -486 -571 -656 -695 -750 -813 -742
Accumulated Other Comprehensive Income / (Loss)		 - - - - 0.00 -0.01 -0.03 -0.13 -0.07 0.01 0.14

Quarterly Balance Sheets for Abeona Therapeutics

This table presents Abeona Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 66 75 134 121 99 246 231 198
Total Current Assets		 57 67 126 113 88 232 216 183
Cash & Equivalents		 4.71 18 34 16 16 164 83 61
Short-Term Investments		 49 45 88 94 68 62 124 107
Accounts Receivable		 2.21 2.23 1.64 1.61 1.62 1.63 1.62 6.71
Inventories, net		 - - - - - 2.69 4.85 6.05
Prepaid Expenses		 0.96 1.81 1.22 1.01 2.01 2.09 2.21 1.95
Plant, Property, & Equipment, net		 4.00 3.77 3.98 4.06 6.95 9.49 10 11
Total Noncurrent Assets		 4.82 4.34 4.12 3.88 4.30 4.48 4.63 4.95
Other Noncurrent Operating Assets		 4.82 4.34 4.12 3.88 4.30 4.48 4.63 4.95
Total Liabilities & Shareholders' Equity		 66 75 134 121 99 246 231 198
Total Liabilities		 44 84 61 75 58 83 60 54
Total Current Liabilities		 8.41 12 17 18 18 35 22 31
Short-Term Debt		 - - 2.22 4.44 8.15 5.56 8.89 13
Accounts Payable		 2.59 3.36 3.10 2.79 5.02 7.34 5.93 4.07
Accrued Expenses		 3.97 2.79 4.92 5.21 3.89 5.50 6.89 5.37
Current Deferred & Payable Income Tax Liabilities		 - - - - - 16 0.34 0.00
Other Current Liabilities		 1.85 5.74 6.60 5.98 0.93 0.62 0.14 8.27
Total Noncurrent Liabilities		 36 72 44 56 40 48 38 23
Long-Term Debt		 - 18 16 14 11 14 11 4.75
Noncurrent Deferred Revenue		 - - - - - - - 0.43
Other Noncurrent Operating Liabilities		 36 54 28 42 29 34 27 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 22 -8.88 73 46 41 164 171 145
Total Preferred & Common Equity		 22 -8.88 73 46 41 164 171 145
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 22 -8.88 73 46 41 164 171 145
Common Stock		 755 772 847 850 867 880 893 904
Retained Earnings		 -733 -781 -774 -804 -825 -716 -722 -759
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.18 -0.13 -0.08 -0.07 -0.05 0.01 -0.02

Annual Metrics And Ratios for Abeona Therapeutics

This table displays calculated financial ratios and metrics derived from Abeona Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 32,732,783.00 39,959,568.00 46,775,257.00 47,944,486.00 51,154,395.00 98,527,723.00 101,917,914.00 17,175,799.00 24,773,317.00 - 54,191,361.00
DEI Adjusted Shares Outstanding		 1,309,311.00 1,598,383.00 1,871,010.00 1,917,779.00 2,046,176.00 3,941,109.00 4,076,717.00 17,175,799.00 24,773,317.00 - 54,191,361.00
DEI Earnings Per Adjusted Shares Outstanding		 -11.09 -13.68 -14.60 -29.55 -37.28 -21.37 -20.83 -2.53 -2.19 - 1.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.43% -72.40% 191.64% -75.87% -100.00% 0.00% -70.00% -52.87% 147.52% -100.00% 0.00%
EBITDA Growth		 -476.76% -28.12% -17.52% -105.96% -24.13% -9.45% -10.12% 57.68% -57.70% -10.87% 222.00%
EBIT Growth		 -492.33% -28.77% -16.56% -108.96% -32.53% -5.62% -8.18% 55.12% -48.82% -10.43% 208.93%
NOPAT Growth		 -492.33% -28.77% -16.56% -108.96% -32.53% -5.62% -10.34% 43.32% 7.42% -36.23% -98.73%
Net Income Growth		 45.75% -50.58% -24.90% -107.44% -34.61% -10.42% -0.83% 53.26% -36.51% -17.62% 211.69%
EPS Growth		 96.53% -20.75% -3.13% -80.30% -26.89% 39.74% 0.00% 0.00% 54.25% 38.74% 165.16%
Operating Cash Flow Growth		 -546.99% -24.86% -74.08% -72.64% -60.62% 44.26% -87.51% 33.78% 14.89% -51.36% -36.26%
Free Cash Flow Firm Growth		 -958.55% 59.27% -14.60% -254.00% 56.02% 49.80% -185.96% 70.07% -43.39% -126.96% -135.68%
Invested Capital Growth		 537.55% 8.60% 7.99% 113.54% -28.82% -81.14% -150.88% -445.16% -46.69% 7.09% 65.34%
Revenue Q/Q Growth		 -1.79% -66.16% 1,343.10% -61.30% -100.00% 42.86% 0.00% -67.46% -1.91% 0.00% 1,355.00%
EBITDA Q/Q Growth		 -45.71% 2.20% -12.54% -16.77% 3.19% 2.21% -57.42% 55.95% -22.54% 11.52% 208.46%
EBIT Q/Q Growth		 -45.34% 1.73% -11.71% -18.93% 2.03% 2.32% -52.74% 53.29% -20.26% 10.40% 196.72%
NOPAT Q/Q Growth		 -45.34% 1.73% -11.71% -18.93% 2.03% 2.32% -55.79% 39.84% -0.58% -5.70% -7.35%
Net Income Q/Q Growth		 39.80% -27.09% -5.60% -18.95% 1.36% 0.71% -57.05% 49.92% -21.18% 10.27% -13.56%
EPS Q/Q Growth		 32.05% -23.08% -3.13% -17.82% 3.21% 14.15% 0.00% 57.23% -40.56% -5.44% -45.99%
Operating Cash Flow Q/Q Growth		 -20.53% -4.13% -7.87% -43.84% 4.15% 26.52% -77.39% 27.22% 11.39% -15.04% -1.86%
Free Cash Flow Firm Q/Q Growth		 21.51% 2.21% -18.25% -99.10% 60.02% -67.38% -17.89% 57.10% -339.20% -64.43% 0.11%
Invested Capital Q/Q Growth		 -7.41% -7.26% -3.03% 81.68% -27.83% -53.62% -122.36% -538.68% -17.73% 23.13% 26.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 73.68%
EBITDA Margin		 -1,730.29% -8,033.45% -3,237.16% -27,626.73% 0.00% -758.19% -2,783.07% -2,498.94% -1,592.14% 0.00% 1,270.09%
Operating Margin		 -1,783.27% -8,320.91% -3,325.69% -28,795.05% 0.00% -814.20% -2,994.53% -3,600.78% -1,346.71% 0.00% -1,536.91%
EBIT Margin		 -1,783.27% -8,320.91% -3,325.69% -28,795.05% 0.00% -814.20% -2,935.93% -2,795.76% -1,680.86% 0.00% 1,193.59%
Profit (Net Income) Margin		 -1,396.73% -7,621.25% -3,263.92% -28,054.95% 0.00% -842.34% -2,831.20% -2,807.36% -1,548.23% 0.00% 1,223.08%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 92.63% 99.65% 94.85% 98.16% 99.86%
Interest Burden Percent		 78.32% 91.59% 98.14% 97.43% 98.95% 103.46% 104.11% 100.77% 97.11% 99.94% 102.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.14%
Return on Invested Capital (ROIC)		 -122.02% -58.11% -62.55% -80.29% 0.00% -195.03% -2,760.54% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -116.00% -48.67% -54.98% -64.55% 0.00% -170.55% -2,729.12% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 81.97% 31.88% 42.25% 43.02% 0.00% 135.07% 2,643.33% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -40.05% -26.22% -20.30% -37.27% -48.82% -59.96% -117.22% -114.85% -260.60% -216.57% 70.05%
Cash Return on Invested Capital (CROIC)		 -169.92% -66.35% -70.23% -152.71% -57.60% -58.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -38.38% -24.99% -19.21% -32.94% 0.00% -43.47% -76.33% -54.98% -91.77% 0.00% 42.29%
Return on Assets (ROA)		 -30.06% -22.89% -18.85% -32.09% 0.00% -44.98% -73.61% -55.21% -84.53% 0.00% 43.34%
Return on Common Equity (ROCE)		 -40.05% -26.22% -20.30% -37.27% -48.82% -59.96% -117.22% -114.85% -260.60% -216.57% 70.05%
Return on Equity Simple (ROE_SIMPLE)		 -21.45% -22.07% -16.06% -42.28% -42.75% -82.14% -200.47% -148.34% -365.49% -144.75% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -17 -19 -41 -54 -57 -63 -36 -33 -45 -89
NOPAT Margin		 -1,248.29% -5,824.63% -2,327.98% -20,156.53% 0.00% -569.94% -2,096.17% -2,520.54% -942.70% 0.00% -1,534.75%
Net Nonoperating Expense Percent (NNEP)		 -6.02% -9.44% -7.57% -15.74% -22.98% -24.48% -31.42% -8.15% -40.35% -28.54% 128.17%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -222.54% -71.35% -49.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.32%
SG&A Expenses to Revenue		 1,376.92% 4,630.66% 1,307.41% 9,953.47% 0.00% 566.95% 721.47% 1,220.37% 542.97% 0.00% 1,117.37%
R&D to Revenue		 453.37% 3,712.54% 2,029.75% 19,157.43% 0.00% 301.39% 1,290.87% 2,048.44% 888.31% 0.00% 460.69%
Operating Expenses to Revenue		 1,883.27% 8,420.91% 3,425.69% 28,895.05% 0.00% 914.20% 3,094.53% 3,700.78% 1,446.71% 0.00% 1,610.58%
Earnings before Interest and Taxes (EBIT)		 -19 -24 -28 -58 -77 -81 -88 -40 -59 -65 69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -23 -27 -56 -69 -76 -83 -35 -56 -62 74
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.62 1.96 4.36 2.55 0.94 1.51 0.81 1.98 8.37 5.50 1.79
Price to Tangible Book Value (P/TBV)		 3.84 3.33 5.55 5.85 1.52 2.26 0.84 1.98 8.37 5.50 1.79
Price to Revenue (P/Rev)		 105.75 675.27 885.77 1,694.67 0.00 15.47 11.45 37.41 35.46 0.00 49.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.01
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.93%
Enterprise Value to Invested Capital (EV/IC)		 2.53 4.16 18.66 3.73 0.77 6.62 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 67.16 434.36 721.19 1,274.04 0.00 6.14 0.00 0.29 20.44 0.00 19.63
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.55
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.64
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.43 0.13
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.30 0.05
Financial Leverage		 -0.71 -0.66 -0.77 -0.67 -0.62 -0.79 -0.97 -1.44 -2.53 -2.24 -1.23
Leverage Ratio		 1.33 1.15 1.08 1.16 1.27 1.33 1.59 2.08 3.08 2.94 1.62
Compound Leverage Factor		 1.04 1.05 1.06 1.13 1.26 1.38 1.66 2.10 2.99 2.94 1.66
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.69% 0.00% 0.00% 0.00% 30.10% 11.18%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.32% 0.00% 0.00% 0.00% 9.41% 6.82%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.37% 0.00% 0.00% 0.00% 20.70% 4.36%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 98.31% 100.00% 100.00% 100.00% 69.90% 88.82%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 -0.31 0.27
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.23 0.00 0.00 0.00 1.28 -2.32
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 -0.21 0.11
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 -0.42 -0.22
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 1.64 0.00 0.00 0.00 1.76 1.92
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 -0.29 -0.09
Altman Z-Score		 -0.25 5.48 48.90 1.17 -1.45 -4.64 -14.00 -15.47 -17.07 -9.25 0.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 27.47 8.37 25.07 4.37 3.42 2.33 3.39 6.83 4.15 6.08 6.93
Quick Ratio		 27.25 8.35 24.59 4.18 3.34 2.26 2.89 6.73 4.07 5.99 6.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -47 -19 -22 -77 -34 -17 -49 -15 -21 -48 -112
Operating Cash Flow to CapEx		 0.00% -2,507.51% -2,634.30% -423.14% -995.72% -2,621.18% -1,581.91% 0.00% -29,140.94% -2,307.04% -957.07%
Free Cash Flow to Firm to Interest Expense		 -7,811.53 -3,181.62 -2,734.65 -7,040.47 -85.15 -4.15 -13.37 -19.88 -50.20 -11.32 -30.01
Operating Cash Flow to Interest Expense		 -1,737.17 -2,169.00 -2,831.88 -3,555.55 -157.05 -8.51 -17.96 -59.08 -88.54 -13.31 -20.41
Operating Cash Flow Less CapEx to Interest Expense		 -1,172.33 -2,255.50 -2,939.38 -4,395.82 -172.82 -8.83 -19.10 -56.90 -88.84 -13.89 -22.54
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.00 0.01 0.00 0.00 0.05 0.03 0.02 0.05 0.00 0.04
Accounts Receivable Turnover		 13.87 2.40 7.25 2.15 0.00 0.00 0.00 0.89 2.66 0.00 1.39
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 5.88 0.54 0.80 0.04 0.00 0.82 0.25 0.16 0.75 0.00 0.81
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.27
Days Sales Outstanding (DSO)		 26.32 151.98 50.37 169.85 0.00 0.00 0.00 411.46 137.24 0.00 262.37
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,349.69
Cash Conversion Cycle (CCC)		 26.32 151.98 50.37 169.85 0.00 0.00 0.00 411.46 137.24 0.00 -1,087.32
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 28 30 32 69 49 9.28 -4.72 -26 -38 -35 -12
Invested Capital Turnover		 0.10 0.01 0.03 0.00 0.00 0.34 1.32 -0.09 -0.11 0.00 -0.25
Increase / (Decrease) in Invested Capital		 34 2.37 2.39 37 -20 -40 -14 -21 -12 2.67 23
Enterprise Value (EV)		 70 125 604 257 38 61 -17 0.41 72 163 114
Market Capitalization		 110 194 741 342 167 155 34 53 124 242 286
Book Value per Share		 $2.07 $2.48 $3.64 $2.80 $3.49 $1.04 $0.42 $1.56 $0.60 $1.01 $2.94
Tangible Book Value per Share		 $0.88 $1.46 $2.86 $1.22 $2.15 $0.70 $0.40 $1.56 $0.60 $1.01 $2.94
Total Capital		 68 99 170 134 178 104 42 27 15 63 179
Total Debt		 0.00 0.00 0.00 0.00 0.00 1.76 0.00 0.00 0.00 19 20
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 1.43 0.00 0.00 0.00 13 7.81
Net Debt		 -40 -69 -138 -85 -129 -93 -51 -52 -53 -79 -171
Capital Expenditures (CapEx)		 -3.39 0.52 0.86 9.24 6.31 1.34 4.15 -1.60 0.13 2.43 7.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.05 -8.02 -2.77 -16 -36 -39 -11 -7.17 -10 -7.87 -3.85
Debt-free Net Working Capital (DFNWC)		 39 61 135 68 94 56 40 45 42 90 188
Net Working Capital (NWC)		 39 61 135 68 94 56 40 45 42 84 175
Net Nonoperating Expense (NNE)		 1.54 5.16 7.83 16 22 27 22 4.06 21 19 -161
Net Nonoperating Obligations (NNO)		 -40 -69 -138 -65 -129 -93 -47 -52 -53 -79 -171
Total Depreciation and Amortization (D&A)		 0.55 0.83 0.74 2.36 7.82 5.60 4.59 4.20 3.11 3.18 4.45
Debt-free, Cash-free Net Working Capital to Revenue		 -100.67% -2,793.38% -330.35% -8,153.96% 0.00% -389.21% -374.87% -506.86% -292.83% 0.00% -66.08%
Debt-free Net Working Capital to Revenue		 3,758.75% 21,297.91% 16,127.24% 33,909.41% 0.00% 561.13% 1,322.30% 3,205.09% 1,209.00% 0.00% 3,222.65%
Net Working Capital to Revenue		 3,758.75% 21,297.91% 16,127.24% 33,909.41% 0.00% 557.83% 1,322.30% 3,205.09% 1,209.00% 0.00% 3,012.65%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($13.25) ($16.00) ($16.50) ($29.75) ($37.75) ($22.75) ($21.50) ($5.53) ($2.53) ($1.55) $1.34
Adjusted Weighted Average Basic Shares Outstanding		 1.31M 1.61M 1.89M 1.92M 3.34M 3.95M 5.90M 7.86M 21.38M 41.05M 52.95M
Adjusted Diluted Earnings per Share		 ($13.25) ($16.00) ($16.50) ($29.75) ($37.75) ($22.75) ($21.50) $0.00 ($2.53) ($1.55) $1.01
Adjusted Weighted Average Diluted Shares Outstanding		 1.31M 1.61M 1.89M 1.92M 3.34M 3.95M 5.90M 17.71M 21.38M 41.05M 66.14M
Adjusted Basic & Diluted Earnings per Share		 ($13.25) ($16.00) ($16.50) ($29.75) ($37.75) ($22.75) ($21.50) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.10M 1.37M 1.67M 1.90M 2.01M 3.71M 3.94M 17.71M 27.36M 48.53M 57.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -17 -19 -41 -54 -57 -40 -33 -33 -45 -89
Normalized NOPAT Margin		 -1,248.29% -5,824.63% -2,327.98% -20,156.53% 0.00% -569.94% -1,338.63% -2,364.75% -942.70% 0.00% -1,534.75%
Pre Tax Income Margin		 -1,396.73% -7,621.25% -3,263.92% -28,054.95% 0.00% -842.34% -3,056.47% -2,817.33% -1,632.31% 0.00% 1,224.79%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3,091.00 -3,980.17 -3,479.50 -5,287.82 -192.73 -19.79 -24.09 -53.71 -140.74 -15.44 18.57
NOPAT to Interest Expense		 -2,163.70 -2,786.12 -2,435.65 -3,701.47 -134.91 -13.85 -17.20 -48.42 -78.93 -10.68 -23.88
EBIT Less CapEx to Interest Expense		 -2,526.17 -4,066.67 -3,587.00 -6,128.09 -208.50 -20.11 -25.23 -51.53 -141.05 -16.02 16.44
NOPAT Less CapEx to Interest Expense		 -1,598.87 -2,872.62 -2,543.15 -4,541.75 -150.68 -14.18 -18.34 -46.25 -79.24 -11.26 -26.02
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Abeona Therapeutics

This table displays calculated financial ratios and metrics derived from Abeona Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 24,755,873.00 24,773,317.00 27,355,037.00 41,186,004.00 43,314,397.00 - 48,533,798.00 51,156,736.00 51,278,539.00 54,191,361.00 57,049,023.00
DEI Adjusted Shares Outstanding		 24,755,873.00 24,773,317.00 27,355,037.00 41,186,004.00 43,314,397.00 - 48,533,798.00 51,156,736.00 51,278,539.00 54,191,361.00 57,049,023.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.48 -0.67 -1.15 0.18 -0.70 - -0.25 2.13 -0.10 -0.38 -0.30
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -116.81% -153.14% -243.99% 143.52% -158.44% 47.48% 64.25% -445.11% 31.46% 1,776.73% -50.98%
EBIT Growth		 -95.86% -131.62% -223.66% 137.99% -145.28% 43.25% 60.98% -485.49% 30.73% 1,569.35% -42.59%
NOPAT Growth		 -20.83% -2.11% -19.04% -141.80% -35.39% -26.22% -37.66% -11.67% -56.52% -37.42% -16.76%
Net Income Growth		 -83.96% -132.99% -246.74% 144.47% -155.74% 43.99% 61.91% 1,369.52% 82.95% -120.17% -41.95%
EPS Growth		 52.00% 15.38% -114.81% 71.74% -31.25% 164.94% 79.31% 757.69% 84.13% -172.00% -25.00%
Operating Cash Flow Growth		 15.39% 34.00% -23.79% -23.34% -112.91% -79.31% -26.58% -48.09% -73.18% -8.42% -7.62%
Free Cash Flow Firm Growth		 8.21% -76.86% 83.82% -176.70% -85.96% -618.65% -302.33% 38.78% -1,729.41% -171.53% 20.22%
Invested Capital Growth		 -695.78% -46.69% -143.53% -13.27% -42.31% 7.09% 55.48% -35.83% 63.89% 65.34% 77.97%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 60.89%
EBITDA Q/Q Growth		 37.30% -47.66% -82.74% 125.72% -472.37% 70.00% -39.63% -145.17% 26.04% 753.98% -112.57%
EBIT Q/Q Growth		 35.18% -40.24% -81.38% 123.04% -518.57% 67.55% -38.24% -125.05% 24.78% 720.80% -113.42%
NOPAT Q/Q Growth		 -7.39% -16.54% -8.49% -78.09% 39.87% -8.65% -18.32% -44.46% 15.72% 4.61% -0.53%
Net Income Q/Q Growth		 28.93% -40.17% -90.33% 123.45% -508.71% 69.30% -29.44% 1,004.76% -104.74% -296.43% 16.54%
EPS Q/Q Growth		 47.83% -60.42% -50.65% 77.59% -142.31% 179.37% -148.00% 812.50% -105.85% -260.00% 16.67%
Operating Cash Flow Q/Q Growth		 44.13% -60.72% -57.42% 12.75% 3.55% -35.35% -11.13% -2.08% -12.79% 15.26% -10.31%
Free Cash Flow Firm Q/Q Growth		 8.68% -86.24% 677.05% -165.98% 119.89% -608.58% -203.13% 80.04% -429.48% 15.25% 10.94%
Invested Capital Q/Q Growth		 -15.45% -17.73% -41.72% 41.20% -45.04% 23.13% 32.09% -79.41% 61.44% 26.22% 56.84%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 80.74% 69.08%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,872.00% 0.00% 2,452.92% -191.69%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,698.00% 0.00% -422.71% -264.14%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,022.75% 0.00% 2,420.09% -201.80%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 27,208.25% 0.00% -377.49% -195.81%
Tax Burden Percent		 99.07% 98.73% 99.49% 100.00% 100.00% 93.34% 100.00% 87.53% 25.35% 99.64% 100.01%
Interest Burden Percent		 96.08% 96.36% 100.34% 101.63% 99.24% 100.60% 97.47% -442.65% 96.35% -15.65% 97.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.48% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -238.81% -260.60% -1,555.11% -127.38% -209.50% -216.57% -271.78% 48.34% 75.90% 70.05% 70.99%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.78% 0.00% 85.75% -19.70%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 57.25% 0.00% -13.38% -19.12%
Return on Common Equity (ROCE)		 -238.81% -260.60% -1,555.11% -127.38% -209.50% -216.57% -271.78% 48.34% 75.90% 70.05% 70.99%
Return on Equity Simple (ROE_SIMPLE)		 -202.91% 0.00% 863.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.93 -9.25 -10 -18 -11 -12 -14 -20 -17 -16 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,987.18% 0.00% -295.90% -184.90%
Net Nonoperating Expense Percent (NNEP)		 -10.61% -13.98% -50.52% 35.64% -26.85% 3.61% 3.24% 82.82% 8.35% -3.53% -0.88%
Return On Investment Capital (ROIC_SIMPLE)		 - -62.37% -109.06% -19.50% -16.67% -18.53% -22.76% -10.89% -8.80% -8.95% -9.89%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.26% 30.92%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,287.25% 0.00% 346.53% 223.65%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,485.75% 0.00% 123.84% 109.58%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,798.00% 0.00% 503.45% 333.22%
Earnings before Interest and Taxes (EBIT)		 -12 -17 -32 7.29 -31 -9.90 -12 -28 -21 131 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -17 -31 7.97 -30 -8.90 -11 -27 -20 133 -17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.73 8.37 0.00 2.38 5.98 5.50 5.58 1.78 1.58 1.79 1.76
Price to Tangible Book Value (P/TBV)		 4.73 8.37 0.00 2.38 5.98 5.50 5.58 1.78 1.58 1.79 1.76
Price to Revenue (P/Rev)		 29.21 35.46 56.66 0.00 0.00 0.00 0.00 726.43 676.88 49.07 17.58
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.08 3.29 4.01 3.86
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.70% 30.42% 24.93% 25.88%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 14.05 20.44 43.92 0.00 0.00 0.00 0.00 210.69 207.62 19.63 7.25
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.55 1.54
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.64 1.64
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 -2.04 0.25 0.41 0.43 0.47 0.12 0.12 0.13 0.12
Long-Term Debt to Equity		 0.00 0.00 -2.04 0.22 0.31 0.30 0.27 0.09 0.06 0.05 0.03
Financial Leverage		 -1.96 -2.53 -8.65 -1.72 -2.15 -2.24 -3.38 -1.31 -1.29 -1.23 -1.16
Leverage Ratio		 2.80 3.08 13.00 2.27 2.75 2.94 5.36 1.61 1.62 1.62 1.60
Compound Leverage Factor		 2.69 2.97 13.05 2.31 2.73 2.96 5.22 -7.11 1.56 -0.25 1.55
Debt to Total Capital		 0.00% 0.00% 196.55% 20.04% 28.95% 30.10% 31.78% 10.68% 10.34% 11.18% 11.09%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 2.43% 6.90% 9.41% 13.43% 3.03% 4.65% 6.82% 8.18%
Long-Term Debt to Total Capital		 0.00% 0.00% 196.55% 17.61% 22.05% 20.70% 18.35% 7.65% 5.69% 4.36% 2.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% -96.55% 79.96% 71.05% 69.90% 68.22% 89.32% 89.66% 88.82% 88.91%
Debt to EBITDA		 0.00 0.00 -0.23 -0.36 -0.27 -0.31 -0.47 -0.25 -0.29 0.27 0.26
Net Debt to EBITDA		 0.00 0.00 0.57 2.04 1.31 1.28 1.60 2.66 2.75 -2.32 -2.20
Long-Term Debt to EBITDA		 0.00 0.00 -0.23 -0.31 -0.20 -0.21 -0.27 -0.18 -0.16 0.11 0.07
Debt to NOPAT		 0.00 0.00 -0.52 -0.46 -0.44 -0.42 -0.40 -0.26 -0.24 -0.22 -0.20
Net Debt to NOPAT		 0.00 0.00 1.29 2.64 2.15 1.76 1.34 2.77 2.26 1.92 1.62
Long-Term Debt to NOPAT		 0.00 0.00 -0.52 -0.41 -0.33 -0.29 -0.23 -0.19 -0.13 -0.09 -0.05
Altman Z-Score		 -13.79 -14.93 -13.66 -5.20 -7.04 -7.59 -8.80 -1.38 -0.95 1.06 -1.79
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.81 4.15 5.61 7.48 6.12 6.08 4.90 6.73 9.74 6.93 5.89
Quick Ratio		 6.65 4.07 5.43 7.38 6.04 5.99 4.77 6.58 9.41 6.70 5.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 20 2.77 21 -14 2.82 -14 -43 -8.68 -46 -39 -35
Operating Cash Flow to CapEx		 -15,961.11% -46,175.00% -2,005.24% -1,783.97% -3,028.22% -2,732.51% -1,313.49% -647.50% -840.75% -1,557.07% -2,118.07%
Free Cash Flow to Firm to Interest Expense		 191.35 25.37 22.57 -13.23 2.56 -13.26 -43.57 -9.07 -51.01 -44.06 -41.79
Operating Cash Flow to Interest Expense		 -54.72 -84.72 -15.27 -11.83 -11.10 -15.30 -18.44 -19.63 -23.52 -20.31 -23.86
Operating Cash Flow Less CapEx to Interest Expense		 -55.07 -84.91 -16.03 -12.50 -11.47 -15.86 -19.84 -22.66 -26.31 -21.61 -24.99
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.05 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.10
Accounts Receivable Turnover		 2.19 2.66 2.54 0.00 0.00 0.00 0.00 0.24 0.25 1.39 3.49
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.67 0.75 0.77 0.00 0.00 0.00 0.00 0.06 0.06 0.81 1.66
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.27 0.93
Days Sales Outstanding (DSO)		 166.54 137.24 143.45 0.00 0.00 0.00 0.00 1,491.94 1,473.23 262.37 104.50
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,259.57 1,349.69 392.32
Cash Conversion Cycle (CCC)		 166.54 137.24 143.45 0.00 0.00 0.00 0.00 1,491.94 -1,786.34 -1,087.32 -287.82
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -32 -38 -53 -31 -46 -35 -24 -43 -16 -12 -5.25
Invested Capital Turnover		 -0.20 -0.11 -0.09 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.25 -1.00
Increase / (Decrease) in Invested Capital		 -28 -12 -32 -3.69 -14 2.67 30 -11 29 23 19
Enterprise Value (EV)		 50 72 154 70 182 163 166 84 83 114 105
Market Capitalization		 104 124 198 175 274 242 231 291 271 286 256
Book Value per Share		 $0.89 $0.60 ($0.32) $1.78 $1.06 $1.01 $0.85 $3.20 $3.34 $2.94 $2.54
Tangible Book Value per Share		 $0.89 $0.60 ($0.32) $1.78 $1.06 $1.01 $0.85 $3.20 $3.34 $2.94 $2.54
Total Capital		 22 15 9.20 92 64 63 61 183 191 179 163
Total Debt		 0.00 0.00 18 18 19 19 19 20 20 20 18
Total Long-Term Debt		 0.00 0.00 18 16 14 13 11 14 11 7.81 4.75
Net Debt		 -54 -53 -45 -105 -91 -79 -65 -206 -188 -171 -150
Capital Expenditures (CapEx)		 0.04 0.02 0.73 0.71 0.40 0.61 1.40 2.90 2.52 1.15 0.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.24 -10 -7.85 -12 -11 -7.87 -6.21 -23 -4.62 -3.85 -3.00
Debt-free Net Working Capital (DFNWC)		 49 42 55 111 99 90 78 203 203 188 165
Net Working Capital (NWC)		 49 42 55 109 94 84 70 198 194 175 152
Net Nonoperating Expense (NNE)		 3.90 7.34 22 -25 20 -2.38 -1.78 -129 -12 4.42 0.95
Net Nonoperating Obligations (NNO)		 -54 -53 -45 -105 -91 -79 -65 -206 -188 -171 -150
Total Depreciation and Amortization (D&A)		 0.96 0.49 0.67 0.68 0.84 1.00 1.27 0.60 0.80 1.78 0.88
Debt-free, Cash-free Net Working Capital to Revenue		 -146.86% -292.83% -224.17% 0.00% 0.00% 0.00% 0.00% -5,638.75% -1,154.00% -66.08% -20.63%
Debt-free Net Working Capital to Revenue		 1,369.17% 1,209.00% 1,566.74% 0.00% 0.00% 0.00% 0.00% 50,825.25% 50,709.75% 3,222.65% 1,136.67%
Net Working Capital to Revenue		 1,369.17% 1,209.00% 1,566.74% 0.00% 0.00% 0.00% 0.00% 49,436.25% 48,487.50% 3,012.65% 1,044.97%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($0.77) ($1.16) $0.19 ($0.63) $0.05 ($0.24) $2.07 ($0.10) ($0.39) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 24.80M 21.38M 27.32M 40.01M 48.08M 41.05M 49.78M 52.52M 54.24M 52.95M 56.62M
Adjusted Diluted Earnings per Share		 ($0.48) ($0.77) ($1.16) ($0.26) ($0.63) $0.50 ($0.24) $1.71 ($0.10) ($0.36) ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 24.80M 21.38M 27.32M 51.23M 48.08M 41.05M 49.78M 66.64M 54.24M 66.14M 56.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.77) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.77M 27.36M 41.19M 43.31M 43.47M 48.53M 51.16M 51.28M 54.19M 57.05M 57.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.93 -9.25 -10 -13 -11 -12 -14 -20 -17 -16 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,987.18% 0.00% -295.90% -184.90%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31,086.25% 0.00% -378.86% -195.79%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -118.43 -159.99 -33.23 6.80 -27.68 -9.15 -12.37 -29.35 -23.45 148.38 -21.20
NOPAT to Interest Expense		 -75.56 -84.83 -10.54 -16.66 -9.75 -10.79 -13.84 -20.85 -18.66 -18.14 -19.43
EBIT Less CapEx to Interest Expense		 -118.77 -160.17 -33.99 6.13 -28.04 -9.71 -13.77 -32.38 -26.25 147.08 -22.33
NOPAT Less CapEx to Interest Expense		 -75.90 -85.01 -11.30 -17.33 -10.11 -11.35 -15.24 -23.88 -21.46 -19.45 -20.55
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Abeona Therapeutics (NASDAQ: ABEO) showed a much stronger balance sheet in Q1 2026, but profitability and operating cash flow remained weak. The company ended the quarter with a large cash and investment position, yet it continued to burn cash in operations and reported a sizable net loss. For retail investors, the key takeaway is that Abeona appears to have liquidity, but it still has to prove it can convert recent revenue growth into sustainable earnings and positive operating cash flow.

  • Strong liquidity position: Q1 2026 cash and equivalents were $61.4 million and short-term investments were $106.9 million, giving the company substantial near-term financial flexibility.
  • Total assets remain high: Abeona reported $198.5 million in total assets, supported mainly by cash and investments.
  • Revenue improved sharply year over year: Q1 2026 revenue was $8.7 million, up from essentially zero revenue in Q1 2025 and above Q4 2025’s $5.4 million.
  • Gross profit stayed positive: The company generated $6.0 million in gross profit in Q1 2026, showing the core revenue stream still carried favorable margins before operating expenses.
  • Investing cash flow was positive in Q1 2026: Net cash from investing activities was $5.0 million, helped by sales and maturities of investments.
  • Debt levels are manageable relative to assets: Total debt included $13.3 million of short-term debt and $4.8 million of long-term debt in Q1 2026, which is not excessive against the company’s liquid assets.
  • Research spending remains elevated: R&D expense was $9.6 million in Q1 2026, consistent with a development-stage biotech investing heavily in its pipeline.
  • Share count has fluctuated over time: Weighted average diluted shares in Q1 2026 were 56.6 million, still reflecting a meaningful dilution over the last year.
  • Operating losses continue: Q1 2026 operating loss was $23.0 million, essentially flat versus the prior quarter and still very large relative to revenue.
  • Cash burn remains significant: Operating cash flow was negative $19.8 million in Q1 2026, indicating the business is still consuming cash to fund operations.

Trends over the last four years point to a business that has recently improved on the top line but remains inconsistent below the line. Through 2024 and much of 2025, Abeona posted recurring operating losses and negative operating cash flow, with quarterly net losses often in the $10 million to $30 million range. Q2 2025 was an outlier, when large investment-related gains briefly drove net income sharply positive, but that did not represent durable operating profitability. By Q1 2026, revenue had improved meaningfully, yet expenses still far exceeded sales.

The balance sheet trend is more encouraging than the income statement trend. In Q1 2025, the company had about $15.9 million of cash and $68.2 million of short-term investments. By Q3 2025 and Q1 2026, liquidity expanded substantially, with cash plus investments staying above $160 million. Equity also recovered from deeply negative territory in Q1 2024 to $144.9 million in Q1 2026. That suggests the company strengthened its financial position materially, likely through financing activity and portfolio gains.

Still, investors should watch a few risks closely. Abeona’s operating expenses remain high, especially SG&A, and operating cash flow has been consistently negative. The company’s quarterly results also show that non-operating income can swing widely, which makes bottom-line earnings less predictable. Until revenue scales enough to offset the cost structure, the company will likely remain dependent on its cash balance and investment portfolio to support operations.

Bottom line: Abeona Therapeutics looks more financially stable than it did a year ago, but it is not yet a self-sustaining profitable business. The improved cash position is a clear positive, while persistent losses and cash burn remain the main concerns for investors.

07/26/26 09:33 PM ETAI Generated. May Contain Errors.

Abeona Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Abeona Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Abeona Therapeutics' net income appears to be on a downward trend, with a most recent value of $71.18 million in 2025, falling from -$14.53 million in 2015. The previous period was -$63.73 million in 2024. See where experts think Abeona Therapeutics is headed by visiting Abeona Therapeutics' forecast page.

Abeona Therapeutics' total operating income in 2025 was -$89.45 million, based on the following breakdown:
  • Total Gross Profit: $4.29 million
  • Total Operating Expenses: $93.74 million

Over the last 10 years, Abeona Therapeutics' total revenue changed from $1.04 million in 2015 to $5.82 million in 2025, a change of 459.6%.

Abeona Therapeutics' total liabilities were at $60.35 million at the end of 2025, a 7.0% decrease from 2024, and a 389.3% increase since 2015.

In the past 10 years, Abeona Therapeutics' cash and equivalents has ranged from $12.60 million in 2020 to $137.75 million in 2017, and is currently $78.44 million as of their latest financial filing in 2025.

Over the last 10 years, Abeona Therapeutics' book value per share changed from 2.07 in 2015 to 2.94 in 2025, a change of 42.0%.


Related Companies

Financial statements for NASDAQ:ABEO last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel